Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years

BACKGROUND: Age is a major risk factor for herpes zoster (HZ) and its potential long-term complication post-herpetic neuralgia (PHN). Due to the significant burden of HZ and PHN on patients' quality of life, it is vital that effective and well-tolerated vaccines are available to prevent HZ in o...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Arnou, Robert, Fiquet, Anne, Thomas, Stéphane, Sadorge, Christine
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Landes Bioscience 2011
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3256327/
https://ncbi.nlm.nih.gov/pubmed/21941091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.7.10.16480
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak